Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Nadroparin; Pancrelipase

Criteria

Inclusion criteria:

• Hormone refractory prostate cancer within 6 months of diagnosis, OR locally advanced (non-metastasized) pancreatic cancer within 3 months of diagnosis, OR non-small-cell lung cancer within 3 months of stage IIIB.

Exclusion criteria:

• Life expectancy of <3 months.

• Poor performance status (Karnofsky <60).

• Need to be on anticoagulants.

• Use of nadroparin (a low molecular weight heparin) for any reason including a history of heparin-induced thrombocytopenia.

• Have brain metastasis.

• At a high risk of bleeding or have a platelet count <50,000/mm3.

• Have very poor kidney function.